CoChat

Non-Viral Delivery of CRISPR/Cas Cargo to the Retina Using Nanoparticles: Current Possibilities, Challenges, and Limitations

Open access

The DOI matches its Crossref record; 191 of the 192 references it cites were found in a registry or an index, and 1 are not checked yet.

Abstract

The discovery of the CRISPR/Cas system and its development into a powerful genome engineering tool have revolutionized the field of molecular biology and generated excitement for its potential to treat a wide range of human diseases. As a gene therapy target, the retina offers many advantages over other tissues because of its surgical accessibility and relative immunity privilege due to its blood–retinal barrier. These features explain the large advances made in ocular gene therapy over the past decade, including the first in vivo clinical trial using CRISPR gene-editing reagents. Although viral vector-mediated therapeutic approaches have been successful, they have several shortcomings, including packaging constraints, pre-existing anti-capsid immunity and vector-induced immunogenicity, therapeutic potency and persistence, and potential genotoxicity. The use of nanomaterials in the delivery of therapeutic agents has revolutionized the way genetic materials are delivered to cells, tissues, and organs, and presents an appealing alternative to bypass the limitations of viral delivery systems. In this review, we explore the potential use of non-viral vectors as tools for gene therapy, exploring the latest advancements in nanotechnology in medicine and focusing on the nanoparticle-mediated delivery of CRIPSR genetic cargo to the retina.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/pharmaceutics14091842

Cites

191 of 192 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Delivery routes of CRISPR/Cas cargo to the mammalian retina. A representative illustration of the major delivery routes of CRISPR/Cas cargo to the retina represented by subretinal and intravitreal injections. The mammalian retina is divided into three main laminar layers: the outer nuclear layer (ONL), the inner nuclear layer (INL), and the ganglion cell layer (GCL). There are six different retinal neuronal cell types and one glial cell type distributed within the nuclear layers: the rod and cone photoreceptor nuclei are located in the ONL, whereas the nuclei of the bipolar (BC), horizontal (HC), amacrine (AC), and Müller (MG) cells are located in the INL. The cell bodies of the ganglion cells (GC) are located in the GCL. The processes of the different cells are extended into two plexiform layers. Processes from the photoreceptor cells are extended into the outer plexiform layer (OPL) to form synapses with the retinal neurons. Processes from the bipolar, horizontal, amacrine, as well as Müller cells are extended into the inner plexiform layer (IPL). The axons of the ganglion cells are directed into the optic nerve through the nerve fibre layer (NFL).
Figure 1 Delivery routes of CRISPR/Cas cargo to the mammalian retina. A representative illustration of the major delivery routes of CRISPR/Cas cargo to the retina represented by subretinal and intravitreal injections. The mammalian retina is divided into three main laminar layers: the outer nuclear layer (ONL), the inner nuclear layer (INL), and the ganglion cell layer (GCL). There are six different retinal neuronal cell types and one glial cell type distributed within the nuclear layers: the rod and cone photoreceptor nuclei are located in the ONL, whereas the nuclei of the bipolar (BC), horizontal (HC), amacrine (AC), and Müller (MG) cells are located in the INL. The cell bodies of the ganglion cells (GC) are located in the GCL. The processes of the different cells are extended into two plexiform layers. Processes from the photoreceptor cells are extended into the outer plexiform layer (OPL) to form synapses with the retinal neurons. Processes from the bipolar, horizontal, amacrine, as well as Müller cells are extended into the inner plexiform layer (IPL). The axons of the ganglion cells are directed into the optic nerve through the nerve fibre layer (NFL).CC BY · PubMed Central
Figure 2 Different Cas-related proteins and their main characteristics for potential use in CRISPR-based gene therapies. A schematic diagram showing the different classes of Cas proteins used to target/edit retinal cells with their relative sizes. The current delivery platforms used with the CRISPR/Cas cargo are AAV, lentivirus, and ribonucleoproteins (RNPs). CRISPR editing can be achieved either in a sustained delivery acting on DNA or as a single-hit even acting on RNA.
Figure 2 Different Cas-related proteins and their main characteristics for potential use in CRISPR-based gene therapies. A schematic diagram showing the different classes of Cas proteins used to target/edit retinal cells with their relative sizes. The current delivery platforms used with the CRISPR/Cas cargo are AAV, lentivirus, and ribonucleoproteins (RNPs). CRISPR editing can be achieved either in a sustained delivery acting on DNA or as a single-hit even acting on RNA.CC BY · PubMed Central
Figure 3 Viral-based delivery vectors. Schematic diagram showing the advantages, limitations, and therapeutic uses of the four main viral-based vehicles for CRISPR-reagents delivery: AAVs, Adenoviruses, Lentiviruses, and Bacteriophages.
Figure 3 Viral-based delivery vectors. Schematic diagram showing the advantages, limitations, and therapeutic uses of the four main viral-based vehicles for CRISPR-reagents delivery: AAVs, Adenoviruses, Lentiviruses, and Bacteriophages.CC BY · PubMed Central
Figure 4 Types of nanoparticles. Schematic diagram showing the different types of nanoparticles, which can be classified into two categories: Organic nanoparticles, including lipid and polymeric particles; and inorganic nanoparticles, including gold nanoparticles, quantom dots, nanotubes, and mesoporous nanoparticles.
Figure 4 Types of nanoparticles. Schematic diagram showing the different types of nanoparticles, which can be classified into two categories: Organic nanoparticles, including lipid and polymeric particles; and inorganic nanoparticles, including gold nanoparticles, quantom dots, nanotubes, and mesoporous nanoparticles.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 192 references

Cited by

See all 41

Metadata

Authors
Salman, A., Kantor, A., McClements, M. E., Marfany, G., Trigueros, S., & MacLaren, R. E.
Affiliations
  • University of Oxford (GB)
  • Centre for Biomedical Network Research on Rare Diseases (ES)
  • Department of Genetics Microbiology and Statistics, University of Barcelona, 08007 Barcelona, Spain
Corresponding author
Salman, Ahmed
Venue
Pharmaceutics
Publisher
MDPI AG
Published
2022-09-01
Volume
14
Issue
9
Pages
1842
ISSN
1999-4923 (ISSN-L)
OpenAlex
W4294169508
Cited by
37
References
192
Citations by year
2026: 9 · 2025: 8 · 2024: 8 · 2023: 10 · 2022: 2
FWCI
0.73
Type
journal article
Language
en
Open access
Locations
  • Pharmaceutics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
NIHR Oxford Biomedical Research Centre
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
Keywords
CRISPR-Cas, non-viral delivery, nanoparticles, retina, ocular gene therapy, gene therapy vectors, blood-retinal barrier, nanomaterials, genome editing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Non-Viral Delivery of CRISPR/Cas Cargo to the Retina Using Nanoparticles: Current Possibilities, Challenges, and Limitations. https://app.cochat.ai/papers/10.3390/pharmaceutics14091842
The paper
Salman, A., Kantor, A., McClements, M. E., Marfany, G., Trigueros, S., & MacLaren, R. E. (2022). Non-Viral Delivery of CRISPR/Cas Cargo to the Retina Using Nanoparticles: Current Possibilities, Challenges, and Limitations. Pharmaceutics. https://doi.org/10.3390/pharmaceutics14091842

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.